BOTOX, NERVE STIMULATION DEVICES, MIRABEGRON, AND ANTICHOLINERGICS VERSUS BEST SUPPORTIVE CARE FOR OVERACTIVE BLADDER: AN UPDATED US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Murray, Brian [1 ]
Miles-Thomas, Jennifer [2 ]
Sussman, David [3 ]
Park, Amy J. [4 ]
Chermansky, Christopher [5 ]
Nguyen, Victor [6 ]
Tung, Amy [7 ]
Gillard, Patrick [7 ]
Lalla, Anjana [7 ]
Nitti, Victor [8 ]
机构：
[1] Capital Reg Urol Surg, Albany, NY USA
[2] Eastern Virginia Med Sch, Virginia Beach, VA USA
[3] Rowan Univ, Sch Osteopath Med, Sewell, NJ USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[6] Curta Consulting Grp, Seattle, WA USA
[7] Allergan, Irvine, CA USA
[8] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2021年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
M73
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE
    El Ouagari, K.
    Pawar, V
    Coombs, J.
    Rubin, J.
    VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
  • [42] COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY
    Erdogan-Ciftci, E.
    Yanik, L.
    Ersoy, Akyol B.
    Safak, K.
    Thuresson, P. O.
    VALUE IN HEALTH, 2019, 22 : S849 - S849
  • [43] Cost-effectiveness analysis of extended-release tolterodine versus immediate-release tolterodine in the management of overactive bladder in spain
    Castro, D
    Soto, J
    Exposito, I
    VALUE IN HEALTH, 2004, 7 (06) : 798 - 798
  • [44] Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France
    Leeuwenkamp, O.
    Smith-Palmer, J.
    Ortiz, R.
    Werner, A.
    Valentine, W.
    Blachier, M.
    Walter, T.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1534 - 1541
  • [45] SACRAL NERVE STIMULATION (SNS) FOR THE TREATMENT OF IDIOPATHIC REFRACTORY OVERACTIVE BLADDER: COST-EFFECTIVENESS COMPARED TO OPTIMAL MEDICAL THERAPY, BOTULINUM TOXIN A (BONT-A) AND PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS)
    Jenks, Julie
    Hamid, Rizwan
    Shah, Julian
    Greenwell, Tamsin
    Betts, Chris
    Walleser, Silke
    Hallas, Nataie
    Ockrim, Jeremy
    JOURNAL OF UROLOGY, 2013, 189 (04): : E560 - E560
  • [46] Sacral Nerve Stimulation (SNS) for the treatment of idiopathic refractory overactive bladder: cost-effectiveness compared to optimal medical therapy, botulinum toxin A (BoNT-A) and percutaneous tibial nerve stimulation (PTNS)
    Ockrim, J. L.
    Jenks, J.
    Shah, P. J. R.
    Greenwell, T. J.
    Wallesesr, S.
    Betts, C.
    Hallas, N.
    BJU INTERNATIONAL, 2013, 111 : 52 - 52
  • [47] Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison
    Vargas, C.
    Balmaceda, C.
    Rodriguez, F.
    Rojas, R.
    Giglio, A.
    Espinoza, M. A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2019, 19 (05) : 609 - 617
  • [48] Cost-Effectiveness Analysis of Ranibizumab versus Verteporfin Photodynamic Therapy, Pegaptanib Sodium, and Best Supportive Care for the Treatment of Age-Related Macular Degeneration in Greece
    Athanasakis, Kostas
    Fragoulakis, Vasilios
    Tsiantou, Vasiliki
    Masaoutis, Panagiotis
    Maniadakis, Nikolaos
    Kyriopoulos, John
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 446 - 456
  • [49] COST-EFFECTIVENESS ANALYSIS OF APATINIB COMPARED WITH BEST SUPPORTIVE CARE IN CHEMOTHERAPY-REFRACTORY ADVANCED OR METASTATIC GASTRIC CANCER IN CHINA
    Qin, S.
    Li, J.
    Yang, L.
    VALUE IN HEALTH, 2017, 20 (05) : A110 - A110
  • [50] Cost-effectiveness analysis of capecitabine maintenance therapy plus best supportive care vs. best supportive care alone as first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma
    Han, Jiaqi
    Lan, Xiaomeng
    Tian, Kun
    Shen, Xi
    He, Jinlan
    Chen, Nianyong
    FRONTIERS IN PUBLIC HEALTH, 2023, 10
12345